NCT00799006已完成1 期
A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Escalating Oral Doses Of PF-04620110 In Otherwise Healthy Overweight And Obese Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- To assess safety and tolerability of PF-04620110 will be assessed by physical examinations, adverse event monitoring, 12 lead ECGs, continuous cardiac monitoring over the first 8 hours after dosing, vital sign and clinical safety laboratory measurements.
研究概览
简要总结
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics following a single oral dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and/or female subjects between the ages of 18 and 55 years
- •Body Mass Index (BMI) of approximately 27 to 35 kg/m2; and a total body weight >50 kg (110 lbs)
排除标准
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
PF-04620110
Experimental
干预措施: PF-04620110 (Drug)
结局指标
主要结局
To assess safety and tolerability of PF-04620110 will be assessed by physical examinations, adverse event monitoring, 12 lead ECGs, continuous cardiac monitoring over the first 8 hours after dosing, vital sign and clinical safety laboratory measurements.
时间窗: 4 days/dose group
The single dose pharmacokinetics of PF-04620110 will be assessed
时间窗: 4 days/dose group
次要结局
- Secondary pharmacodynamic endpoints will include postprandial lipid metabolism measures(1 day/dose group)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy VolunteersOverweightHealthyObesityNCT00959426Pfizer71
已完成
1 期
Single Dose Escalation Study of PF-05190457 in Healthy VolunteersDiabetes Mellitus, Type IINCT01247896Pfizer26
已完成
1 期
A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese SubjectsHealthyNCT01146327Pfizer60
已完成
1 期
A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes PatientsType 2 Diabetes PatientsNCT01298518Pfizer48
已完成
1 期
A Single Dose Study Of PF-04620110 In Healthy SubjectsHealthyNCT01166217Pfizer12